Semaglutide Research: GLP-1 Receptor Signaling

Semaglutide is a synthetic analog of GLP-1 (glucagon-like peptide-1), engineered for a long half-life so it can be studied as a once-weekly agonist. More than any single compound, it's the one that pushed incretin biology into mainstream conversation. Human research is extensive; this is an educational summary of that research, and the material here is supplied strictly for laboratory Research Use Only.

A long-acting GLP-1 agonist

GLP-1 is an incretin hormone that links nutrient sensing in the gut to insulin signaling and satiety pathways. Reviews trace the discovery and engineering of semaglutide from the native hormone toward a stabilized, long-acting analog (Knudsen & Lau, Front Endocrinol, 2019). [1] Companion research even developed an orally absorbed formulation, a notable pharmacology achievement for a peptide (Buckley et al., Sci Transl Med, 2018). [2]

The clinical-research record

The STEP program studied semaglutide for body-weight outcomes in overweight/obesity research populations (Wilding et al., N Engl J Med, 2021). [3] This large trial base is why semaglutide anchors so much metabolic-research discussion.